These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 20429405)
1. [Contraceptives in the perimenopause: Safe prevention and treatment of menopausal symptoms?]. Zahradnik HP Med Monatsschr Pharm; 2010 Apr; 33(4):143-4. PubMed ID: 20429405 [No Abstract] [Full Text] [Related]
3. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Wildemeersch D; Schacht E Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454 [TBL] [Abstract][Full Text] [Related]
4. [Contraconception in women with systemic lupus erythematosus]. Cravioto Mdel C; Durand-Carbajal M; Sánchez-Guerrero J Rev Invest Clin; 2009; 61(2):150-9; discussion 159-60. PubMed ID: 19637729 [No Abstract] [Full Text] [Related]
5. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). van Vliet HA; Tchaikovski SN; Rosendaal FR; Rosing J; Helmerhorst FM Thromb Haemost; 2009 Apr; 101(4):691-5. PubMed ID: 19350113 [TBL] [Abstract][Full Text] [Related]
6. [One year experience of levonorgestrel-releasing intrauterine device]. Lähteenmäki P; Shain RN; Ratsula K; Toivonen J; Holden AE; Rosenthal M; Luukkainen T Duodecim; 1991; 107(1):26-31. PubMed ID: 1364704 [No Abstract] [Full Text] [Related]
7. [Contraception in the premenopausal period]. Schwartz U Gynakologe; 1986 Dec; 19(4):254-8. PubMed ID: 3817598 [No Abstract] [Full Text] [Related]
8. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839 [TBL] [Abstract][Full Text] [Related]
12. [The use of hormonal contraception in perimenopause is still a hazard?]. Buttarelli M; Ghezzi F; Cromi A; Raio L; Franchi M Minerva Ginecol; 2001 Dec; 53(6):421-9. PubMed ID: 11723427 [TBL] [Abstract][Full Text] [Related]
13. [Hormonal contraception in the perimenopause]. Butarelli M; Bodmer C; Wunder D; Birkhäuser M Ther Umsch; 2001 Sep; 58(9):555-63. PubMed ID: 11594155 [TBL] [Abstract][Full Text] [Related]
14. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124 [TBL] [Abstract][Full Text] [Related]
15. Severe seborrhoeic dermatitis: side-effect of the Mirena intra-uterine system. Karri K; Mowbray D; Adams S; Rendal JR Eur J Contracept Reprod Health Care; 2006 Mar; 11(1):53-4. PubMed ID: 16546818 [TBL] [Abstract][Full Text] [Related]
19. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Tjalma WA; Trinh XB; van Dam PA Obstet Gynecol; 2006 Jan; 107(1):207-8; author reply 208. PubMed ID: 16394064 [No Abstract] [Full Text] [Related]
20. Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review. Peled Y; Perri T; Pardo Y; Kaplan B Menopause; 2007; 14(3 Pt 1):550-4. PubMed ID: 17224852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]